Navigation Links
Drug that restricts blood supply to prostate tumors delays disease progression
Date:6/8/2010

A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University.

Tasquinimod is a so-called "anti-angiogenesis" drug that squeezes off blood supply to prostate tumors by blocking new blood vessel development. Tumors require these vast networks of blood vessels to supply nutrients.

The multicenter trial at seven institutions, including Johns Hopkins, enrolled prostate cancer patients whose disease had spread to take a once-daily pill for four weeks. At six months, 57 percent of men taking tasquinimod had no disease progression as compared with 33 percent taking a placebo. Overall, the drug added approximately 12 weeks of time that the disease did not worsen (progression-free survival).

The most common side effects included gastrointestinal problems, fatigue and bone pain, and some rare occurrences of heart attack, stroke and deep vein thrombosis.

"Given these results, we feel it is reasonable to move forward with Phase III studies," says Michael Carducci, M.D., professor at the Johns Hopkins Kimmel Cancer Center, who will lead the next phase of an international study of the drug. "After exploring the drug as a single agent, we may study it in combination approaches with other prostate cancer drugs."

Research leading to tasquinimod began in the early 1990s when John Isaacs, Ph.D., professor at the Johns Hopkins Kimmel Cancer Center, found that a drug called linomide, which had been tested in multiple sclerosis, restricted blood supply to prostate tumors. However, the drug's cardiac side effects were too toxic for humans, so Isaacs in collaboration with the pharmaceutical company Active Biotech identified tasquinimod for clinical testing after searching for drugs similar to linomide with the same blood vessel action but with less toxicity.

Isaacs says that tasquinimod works by stopping new blood vessel development around the tumor, but does not make existing vasculature disappear. "The idea for anti-angiogenesis drugs is not to prevent tumors from developing; rather, it is to stabilize disease," says Isaacs, who is conducting additional laboratory studies to identify the drug's precise cellular target.

Funding for the study was provided by Active Biotech, manufacturer of tasquinimod, and the U.S. Department of Defense.

Carducci is a paid consultant to Active Biotech and the terms of this arrangement are being managed in accordance with policies set by the Johns Hopkins University.


'/>"/>

Contact: Vanessa Wasta
wastava@jhmi.edu
410-955-1287
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Psychologists Say New Jerseys Largest Health Plan Violates Patient Privacy, Restricts Access to Care and Wastes Taxpayer Money
2. ASCO data show serum DNA blood tests detect cancers with high sensitivity and specificity
3. Glucose Tattoo Could Track Blood Sugar Levels for Diabetics
4. DUI Phoenix Attorney Earns Not Guilty Verdict and Hung Jury in .104 Blood Alcohol Content DUI Case
5. First paper dipstick test for determining blood type
6. Nottingham research leads to blood test for early detection of cancer
7. Blood flows differently through the brains of schizophrenic patients
8. Report Finds Control of High Blood Pressure Improving
9. Frequent Doctor Visits Help Diabetics Control Blood Pressure
10. Fewer Sugary Drinks, Less High Blood Pressure
11. A new cancer vaccine starves tumors of blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... TruClinic Inc. announced ... company based in New York. , “Ensuring an intuitive, user-friendly patient experience is ... Those two fundamental reasons are the reasons this acquisition is an obvious one,” ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... has challenges as they transition from military to civilian life. Body image dissatisfaction ... million who experience poorer health and greater occurrence of chronic mental health conditions ...
(Date:2/27/2017)... ... 27, 2017 , ... Bo Chen, PhD is the recipient of the 2017 ... during the Plenary Session at ASLMS 2017, the Annual Conference of the American Society ... April 5-9, 2017. , During the Plenary Session on April 7, Dr. Chen ...
(Date:2/27/2017)... ... 2017 , ... Hotze Health & Wellness Center (HHWC), a ... New Guest Director. , Brandl is a dynamic and influential executive leader ... his professional career at Omnium Worldwide, now known as West Corporation, and handled ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... Shamanic Healing and Spiritual Awakening, is happy to announce her “Spring Rejuvenation ... and body, these individual customized retreats offer the winter-weary soul an excellent opportunity ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... AMSTERDAM , Feb. 27, 2017   ... AEX: PHIA), a global leader in health technology, ... and Drug Administration (FDA) to market its ElastQ ... EPIQ family of ultrasound systems. ElastQ Imaging enables ... stiffness, which is essential for the diagnosis of ...
(Date:2/27/2017)...  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI ) ... th Annual Healthcare Conference on Monday, March 6, ... MA. A live webcast of Infinity,s presentation ... website at www.infi.com , and will be available ... Infinity,Infinity is an innovative biopharmaceutical company dedicated to advancing ...
(Date:2/27/2017)... A recent research report published by Grand View Research, ... to reach a value of $55.8 billion by 2025. Earlier in ... have legalized marijuana for medical uses. In 2016, states such as ... North Dakota , Ohio and ... in medical applications such as chemotherapies and pain management. The growing ...
Breaking Medicine Technology: